Three-dimensional (3D) printing has gained substantial interest among scientists and surgeons over the past decade due to its broad potential in medical applications. Its clinical utility has been increasingly recognized, demonstrating promising outcomes for patient care. Currently, 3D printing technology enables surgeons to enhance operative precision by facilitating the creation of patient-specific anatomical models, customized implants, biological tissues, and even surgical instruments. This personalization contributes to improved surgical outcomes, reduced operative times, and shorter postoperative recovery periods. Furthermore, 3D printing significantly aids in the customization of prostheses to conform closely to individual anatomical structures. Beyond therapeutic applications, 3D printing serves as a valuable educational tool in medical training. It enhances case-specific visualization, elucidates fracture mechanisms, and provides tangible models for simulation-based practice. Although the use of 3D printing might be seen as useful mostly in orthopedics, it has expanded into multiple medical specialties, including plastic surgery, dentistry, and emergency medicine. Presently, 3D-printed constructs are routinely employed for preoperative planning, prosthetic development, fracture management, and the fabrication of patient-specific surgical tools. Futuristically, the integration of 3D printing into clinical practice is expected to play a pivotal role in the advancement of personalized medicine, offering substantial benefits for both healthcare providers and patients.

Colorectal cancer (CRC) is one of the deadliest and most frequently occurring cancers worldwide. Often diagnosed in advanced stages, it requires more challenging treatment. However, emerging studies highlight the possible role of microRNAs (miRNAs) in the screening, diagnosis, and prognosis of CRC. MiRNAs modulate gene expression and can play both roles in tumor suppressors and oncogenes. In CRC, they influence epithelial–mesenchymal transition (EMT), cell proliferation and migration, apoptosis, autophagy, and patients’ treatment response. In clinical applications, they can be used as predictive and prognostic biomarkers as well as for matching the most suitable treatments. Despite its growing popularity, there is still much to discover about their potential usage in medicine.

Depression is one of the most prevalent psychiatric disorders worldwide, with a steadily increasing incidence and complex, multifactorial pathophysiology. Beyond classical neurochemical mechanisms, growing evidence points to the role of systemic low-grade inflammation and immuno-metabolic disturbances in its development. Gut microbiota dysbiosis has emerged as a key factor linking metabolic, immune, and neuroendocrine pathways, potentially exacerbating neuroinflammation and contributing to the onset and progression of depressive symptoms. Immune activation, which is a result of gut dysbiosis, may play a crucial role in the pathogenesis of immuno-metabolic depression. Thyroid dysfunction appears to be an important, yet insufficiently understood component of this network. Thyroid hormones play a crucial role in regulating metabolism, immune responses, and central nervous system function. Alterations in thyroid function, even within subclinical ranges, have been associated with mood disturbances and may share common inflammatory and metabolic pathways with depression. Furthermore, emerging data suggest that gut microbiota may influence thyroid hormone metabolism, including deiodinase activity, linking dysbiosis with thyroid axis dysregulation. Despite these insights, the integrated interactions between thyroid function, gut microbiota, metabolic syndrome, and inflammation in depression remain largely unexplored. This review explores current evidence to highlight gaps in existing research and synthesizes current knowledge, aiming to clarify mechanisms underlying immuno-metabolic depression. Understanding these relationships may provide a rationale for redefining depression as an immuno-metabolic disorder and support the development of more integrative therapeutic strategies targeting not only the brain, but also the gut-thyroid axis.

Background: Needle arthroscopy can alter not only portal size but also the diagnostic and treatment pathway by enabling direct visualization under local anesthesia and selected limited interventions. Its diffusion across joints, however, may be outpacing clinical validation. Methods: This PRISMA-ScR-guided review mapped PubMed/MEDLINE-indexed primary publications from database inception through 31 July 2026. The quantitative flow is therefore an auditable but incomplete evidence map rather than a complete census of the technology; studies indexed exclusively outside PubMed may have been missed. Backward reference-list screening was used as a completeness check, while earlier Scopus, Web of Science, and Cochrane histories were retained as sensitivity sources and not pooled into the quantitative flow. Two reviewers independently screened and charted records using a shared form. Reports were de-duplicated by PMID, DOI, and normalized title and characterized by anatomy, design, application, platform, outcomes, harms reporting, study-design hierarchy, and principal methodological limitation. Technical or cadaveric feasibility was analyzed separately from clinical and comparative evidence. Results: The final map comprised 105 unique primary publications: 49 technical, 41 clinical, and 15 cadaveric. Technical and cadaveric reports (64/105, 61.0%) outnumbered clinical reports (41/105, 39.0%), limiting estimation of clinical effectiveness. Ninety publications (85.7%) appeared from 2021 onward; the 2026 count is incomplete because the search ended on 31 July. For descriptive display across the complete map, nine reports (8.6%) were in Levels I–II and 93 (88.6%) in IV–V; among the 41 clinical reports, 29 (70.7%) were IV–V and 12 (29.3%) were I–III. NanoScope accounted for 87 of 107 platform mentions (81.3%). Diagnostic and second-look applications had the most consistent comparative rationale, but lesion-specific estimates varied by joint and reference standard. Reported harms were generally minor where surveillance was described, but rare-harm inference was limited by small samples and inconsistent adverse-event ascertainment. Conclusions: The field remains promising but unproven: technical breadth exceeds comparative clinical validation. Because the quantitative evidence map is PubMed/MEDLINE-only and dominated by technical, cadaveric, and IV–V reports, current evidence is insufficient to estimate clinical effectiveness or justify replacement of MRI or conventional arthroscopy. Needle arthroscopy should therefore be viewed as an indication-specific complement and a hypothesis-generating technology rather than a replacement platform. Multicentre comparative studies and randomized trials, where ethically and practically feasible, are needed to test patient benefit and clinical application.

Early-onset colorectal cancer (EOCRC), defined as colorectal cancer diagnosed before age 50, has become an increasing global public health concern. Incidence rates have risen among younger adults in many countries, despite stable or declining rates in older populations. This review examines global EOCRC epidemiology, potentially modifiable risk factors, and projected future disease burden. Evidence from international cancer databases, population-based registries, and observational studies is synthesised, considering differences by age, sex, geographic region, and tumour location. Key risk factors include obesity, metabolic dysfunction, dietary patterns, physical inactivity, alcohol consumption, tobacco use, antibiotic exposure, and gut microbiome alterations. The review also evaluates temporal trends and projections of incidence, prevalence, and mortality. Although increasing incidence may reflect changing lifestyles, metabolic health, environmental exposures, and other early-life risk factors, their relative contributions remain incompletely understood. Improved understanding of EOCRC epidemiology and future burden may help identify high-risk populations, guide targeted prevention strategies, inform public health policy, and support discussions on earlier colorectal cancer detection and screening.